Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bristol-Myers Squibb ( (BMY) ) just unveiled an announcement.
Bristol Myers Squibb reported robust third-quarter results for 2024, with revenues rising to $11.9 billion, marking an 8% increase (10% when adjusted for foreign exchange). The company’s Growth Portfolio and U.S. approval of Cobenfy for schizophrenia played significant roles in this performance. Despite some challenges like generic erosion of Sprycel, the firm saw strong cash flow and increased revenue guidance. Investors should note the balance of GAAP and non-GAAP figures, reflecting strategic financial moves and a focus on sustainable growth.
For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.
